Chemo Pharma Laboratories Limited, a pharmaceutical company listed on the Bombay Stock Exchange (BSE), has initiated the process to reclassify a member of its promoter group as a public shareholder. The company submitted an application to the BSE on September 10, 2025, seeking approval for this change in shareholder categorization.

Reclassification Details

The application pertains to Ms. Shanta Somani, who is currently classified as part of the Promoter Group. According to the company's filing:

• Shareholder: Ms. Shanta Somani
• Current Category: Promoter Group Shareholder
• Proposed Category: Public Shareholder
• Shareholding: 0 shares (0.00% of the company's equity)

Regulatory Compliance

The reclassification request has been made under Regulation 31A of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations. This provision allows for the reclassification of promoters as public shareholders under specific conditions.

Company's Statement

In its official communication to the BSE, Chemo Pharma Laboratories stated:

"This is with reference with the captioned subject, and in compliance of Regulation 31A of SEBI LODR Regulations and amendment(s) thereto, we wish to inform you that the Company has made an application for approval to BSE Limited (BSE) on September 10, 2025 for reclassification of person forming part of the Promoter Group from 'Promoter Group Shareholder' category to 'Public Shareholder' category under the provisions of the SEBI LODR Regulations."

Implications

While the reclassification does not involve any change in Ms. Somani's shareholding, which stands at zero, it may have implications for the company's promoter group structure and regulatory reporting. The move could potentially affect the overall promoter holding percentage and the public float of the company's shares.

Investors and market participants will be watching for the BSE's decision on this application, as it may influence the perception of the company's ownership structure. The outcome of this reclassification request will be subject to regulatory scrutiny and approval from the stock exchange.

Chemo Pharma Laboratories Limited, a pharmaceutical company listed on the Bombay Stock Exchange, has announced significant changes in its compliance leadership. The company, in a regulatory filing on September 12, 2025, disclosed the resignation of its Company Secretary and Compliance Officer and the immediate appointment of a successor.

Resignation of Ms. Bhawna Rajput

Ms. Bhawna Rajput (ACS 72357) has stepped down from her role as Company Secretary and Compliance Officer of Chemo Pharma Laboratories Limited. According to the company's statement, Ms. Rajput cited preoccupation with other assignments as the reason for her departure. Her resignation was tendered and accepted on September 12, 2025, with immediate effect.

Appointment of Mr. Aditya Agarwal

In a swift transition, the Board of Directors of Chemo Pharma Laboratories Limited convened a meeting on the same day and approved the appointment of Mr. Aditya Agarwal (ACS 53202) as the new Company Secretary and Compliance Officer. Mr. Agarwal's appointment also took effect from September 12, 2025, ensuring continuity in this critical compliance role.

About the New Appointee

Mr. Aditya Agarwal brings a strong educational background and relevant expertise to his new position. He is a qualified Company Secretary with specialized knowledge in legal, secretarial, and listing compliances. His academic credentials include an MBA and an M.Com degree, which complement his professional qualifications.

The company highlighted Mr. Agarwal's experience and his proven ability to independently manage statutory requirements while contributing to organizational growth. He is described as a collaborative team player with an ownership mindset, focused on delivering high-quality strategic solutions to complex challenges.

Board Meeting Details

The Board meeting where these changes were approved commenced at 3:15 PM and concluded at 3:45 PM on September 12, 2025, at the registered office of the company. Mr. Agarwal is not related to any existing directors of Chemo Pharma Laboratories Limited, maintaining the independence of the compliance function.

Regulatory Compliance

These leadership changes were disclosed in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has assured that all necessary formalities regarding Ms. Rajput's resignation will be completed in due course.

Chemo Pharma Laboratories Limited, with its registered office in Kalyan, Maharashtra, and corporate office in Ahmedabad, Gujarat, continues to operate under the leadership of Mr. Ruchit Mehta, the Managing Director and Chief Executive Officer.